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Key points
† T-elevation after
intravascular injection of
a small bupivacaine test
dose are caused by
epinephrine.
† This pig study
demonstrated that
higher doses of i.v.
infused bupivacaine can
cause T-wave elevation.
† Intravascular injection
of large amounts of
bupivacaine can be
detected by changes in
ECG.
† Bupivacaine-induced T-
wave elevation is not a
reliable indicator for early
detection of inadvertent
systemic injection.
† Bupivacaine-induced
T-ware elevation is a sign
of impeding cardiac
toxicity, especially during
fast injection.
Background. It is controversial as to whether T-wave elevation is caused by local
anaesthetics, epinephrine, or their combination. It has been shown that T-elevation after
intravascular injection of a small bupivacaine test dose is caused by epinephrine and not
by bupivacaine. The aim of this study was to investigate ECG changes with higher doses
of i.v. bupivacaine.
Methods. Thirty neonatal pigs were anaesthetized with sevoflurane and their tracheas
intubated and artificially ventilated. Under steady-state conditions, bupivacaine was
continuously infused (flow rate 3.2 ml kg21 min21) by a syringe infusion pump through a
central venous catheter. Group 1 received bupivacaine 0.125%, Group 2 bupivacaine
0.5%. The ECG was continuously printed and subsequently analysed for alterations in
heart rate, ventricular de- and repolarization, and arrhythmias at 1.25, 2.5, and 5 mg
kg21 bupivacaine infused.
Results. Sinus rhythm persisted in all pigs. Heart rate decreased progressively in both
groups, but this was significantly more pronounced in Group 1. T-wave elevation occurred
in 40% and 0% (Groups 1 and 2) at 1.25 mg kg21, in 80% and 0% at 2.5 mg kg21, and
in 93% and 80% at 5 mg kg21 bupivacaine infused. There were significant differences
between the two groups at 1.25 and 2.5 mg kg21 infused.
Conclusions. Higher doses of i.v. infused bupivacaine can cause T-elevation. With slower
injection technique, T-elevation can already be detected at lower bupivacaine doses
administered.
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Local anaesthetics (LA) for regional anaesthesia in children
are usually administered under general anaesthesia.1 Since
neurological signs of LA toxicity in the event of inadvertent
intravascular administration of LA are missing under
general anaesthesia, ECG monitoring for the detection of
LA-related changes, particularly the development of T-wave
elevation, is recommended to detect inadvertent intravascu-
lar administration of LA before severe cardiovascular com-
promise or collapse occurs.1 – 4
It is controversial as to whether T-wave elevation is
caused by LA, epinephrine, or their combination.4 Recent
research in neonatal pigs revealed that the formation of
increased T-waves after injection of a common LA test
dose is mainly caused by epinephrine and not by bupiva-
caine.5 However, there is evidence suggesting that higher
doses of bupivacaine may result in similar alterations.5 6
The aim of this study was to investigate the course of ECG
alterations during continuous i.v. infusion of bupivacaine in
neonatal pigs with special regard to the development of
T-wave elevation.
Methods
After approval from the local ethics committee for animal
experiments, 30 healthy male and female neonatal pigs
(up to 6 weeks of age) were included. The pigs had free
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access to food until 1 h before induction of anaesthesia.
Anaesthesia was induced by the inhalation route using sevo-
flurane. After establishing venous access in an auricular vein,
the trachea was intubated and the lungs were artificially ven-
tilated using pressure-controlled ventilation. Anaesthesia
was maintained using sevoflurane in oxygen/air 1:1.
Monitoring consisted of pulse oximetry, three-lead ECG,
invasive arterial pressure measurement after cannulation of
the carotid artery, end-tidal gas analysis (sevoflurane, O2,
CO2), and rectal temperature control. Under steady-state
conditions, bupivacaine was continuously infused (flow rate
3.2 ml kg21 min21) through a central venous catheter at a
dose rate of 4 mg kg21 min21 (Group 1: bupivacaine
0.125%) or 16 mg kg21 min21 (Group 2: bupivacaine 0.5%)
using a syringe pump (Alaris TIVA, IVAC Corporation, Hamp-
shire, UK).
The ECG lead with best representation of P-wave,
QRS-complex, and T-wave was printed7 and analysed after
the experiment for alterations in heart rate, ventricular de-
and repolarization, and arrhythmias at 1.25, 2.5, and 5 mg
kg21 bupivacaine infused by a blinded paediatric cardiologist
and anaesthetist. Special attention was given to the appear-
ance of T-wave elevation. T-wave elevation of ≥25% baseline
was considered a positive response.3 8
In each group, the percentage of heart rate change and
the occurrence of positive T-wave elevation were compared
between different amounts (1.25, 2.5, and 5 mg kg21) of
bupivacaine administered. The Friedmann test followed by
the Bonferroni corrected group comparisons using the Wil-
coxon test was used for heart rate, and the x2 test was
used to analyse the T-wave elevation data. Comparisons
were made between slow and fast bupivacaine
administration (Groups 1 and 2). Percentage change in
heart rate was analysed using the Mann–Whitney U-tests
and the occurrence of positive T-wave elevations between
the groups was analysed with x2 tests at corresponding
doses of bupivacaine administered. A P-value of ≤0.05 was
considered to be significant. SPSS, version 16.0 (SPSS Inc.,
Chicago, IL, USA), was used for all analyses.
Results
Thirty male and female piglets weighing 4.5–6.2 kg (median
5.1 kg) were investigated. Changes in heart rate and T-wave
elevation are shown in detail in Table 1. T-wave increases as
percentage above baseline demonstrated a huge variability
in degree of T-wave elevation (Fig. 1). Examples of typical
and extreme T-wave increases after the infusion of 1.25,
2.5, and 5 mg kg21 bupivacaine are shown in Figures 2 and
3. T-wave elevation ≥25% baseline was considered a positive
response. This occurred in 40% and 0% (Groups 1 and 2) at
1.25 mg kg21, in 80% and 0% at 2.5 mg kg21, and in 93%
and 80% at 5 mg kg21 bupivacaine infused. There were sig-
nificant differences between the two groups at 1.25 and 2.5
mg kg21 infused (Fig. 4). The probability of T-wave elevation
was high at 2.5 and 5 mg kg21 bupivacaine infused in
Group 1, but only at 5 mg kg21 in Group 2. Heart rate
decreased significantly and progressively in both groups,
but this was significantly more pronounced in Group 1
(Fig. 5). Sinus rhythm persisted in all animals. Neither a
higher degree AV block, nor a complete bundle branch
block, nor premature atrial, nor ventricular contractions
were observed during bupivacaine infusion until 5 mg kg21.
Table 1 ECG alterations after i.v. infusion of 1.25, 2.5, and 5 mg kg21 bupivacaine (n¼30 piglets) at an infusion rate of 4 mg kg21 min21 (Group 1)
or 16 mg kg21 min21 (Group 2). Results are given in median and range. ‡Significant differences between 1.25 and 2.5 mg kg21 bupivacaine
infused. †Significant differences between 2.5 and 5 mg kg21 bupivacaine infused. *Significant differences between 1.25 and 5 mg kg21
bupivacaine infused. #Significant differences between Groups 1 and 2. Infusion time, the time needed to fill the catheter with bupivacaine was
1.3 s for both drug rates (same infusion rate) and is therefore neglected
Bupivacaine infused Parameters All (n530) Group 1 (n515) Group 2 (n515)
1.25 mg kg21 Infusion time (s) 18.8 4.7
Change in heart rate (beats min21) 25 (0 to 223) 0 (0–0)
Change in heart rate (%)# 0 (0 to 214) 24 (0 to 214) 0 (0–0)
T-elevation (mm) 2 (1–6) 3 (1–5)
T-elevation (%) 0 (0–100) 0 (0–100) 0 (0–0)
T-elevation (yes/no)# 6/24 6/9 0/15
2.5 mg kg21 Infusion time (s) 37.5 9.4
Change in heart rate (beats min21) 211 (22 to 226) 22 (0 to 213)
Change in heart rate (%)# 24 (0 to 216) 28 (21 to 216)‡ 21 (0 to 211)‡
T-elevation (mm) 3 (1–8) 3 (1–5)
T-elevation (%) 0 (0–40) 50 (0–400) 0 (0–0)
T-elevation (yes/no)# 12/18 12/3 0/15
5 mg kg21 Infusion time (s) 75 18.8
Change in heart rate (beats min21) 226 (0 to 245) 210 (0 to 233)
Change in heart rate (%)# 213 (0 to 229) 220 (0 to 229)†,* 26 (0 to 228)†,*
T-elevation (mm) 3.5 (1–13) 4 (1–11)
T-elevation (%) 100 (0–800) 133 (0–800) 67 (0–200)
T-elevation (yes/no) 26/4 14/1 12/3
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Discussion
This study investigated whether bupicavaine alone can cause
T-wave alteration in the ECG when systemically adminis-
tered. The main findings were that i.v. administered bupiva-
caine alone causes T-wave elevation in a high percentage
of subjects particularly at larger doses and with slower injec-
tion, T-elevation can already be detected at lesser bupiva-
caine doses.
Reliable signs of inadvertent systemic application of LA in
anaesthetized children are of importance in order to avoid
severe systemic LA toxicity, in particular haemodynamic col-
lapse. The results of this study clearly indicate that not only
systemically administered epinephrine5 but also bupivacaine
cause T-wave elevation, particularly at larger doses. This
explains the confusion about origin and reported varying sen-
sitivity of ECG for the detection of systemic administration of
LA.4 However, as shown by the current animal model, the sen-
sitivity of bupivacaine-induced T-wave elevation for detecting
inadvertent systemic LA administration is not 100%, demon-
strates a large variability in T-wave elevation, and becomes
mainly visible after doses corresponding to the maximum rec-
ommended dose for humans.9 10 Therefore, bupivacaine-
induced T-wave elevation is a sign for impending cardiac tox-
icity and not helpful for early detection of inadvertent intra-
vascular administration. In contrast, T-elevation caused by
an epinephrine containing standard test dose of LA is the
effect of epinephrine and has a sensitivity of 93%.5 In this situ-
ation, no adverse consequences have to be anticipated.5 11 12
The study results confirm the previously reported obser-
vation that not only epinephrine in a normal test dose
alone or in combination with bupivacaine but also bupiva-
caine systemically administered in a twice fold test dose
can evoke T-wave elevation.5 Nystro¨m and colleagues13
investigated acute bupivacaine overdose until near cardiac
arrest in 12 adult male pigs (23–25 kg) sedated with keta-
mine and then anaesthetized with halothane. They also
found significant increases in T-wave amplitude [+66%
above baseline in maximum (mean)]. Tanaka and col-
leagues6 reported a 2-month-old healthy infant demonstrat-
ing significantly increased T-wave amplitude after the
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Fig 1 T-wave increase in percentage above baseline at different
amounts of bupivacaine infused. n¼15 in both groups.
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Fig 2 Typical ECG before (A), after 1.25 mg kg21 (B), 2.5 mg kg21 (C), and 5 mg kg21 (D) bupivacaine infused (Pig no. 1–2).
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accidental systemic administration of a near full-dose lido-
caine plus bupivacaine when performing a caudal block.
The QT interval is a measure from the body surface of the
time required for ventricles of the heart to repolarize. Pro-
longation or abbreviation of the QT interval occurs when
the action potential of a significant number of cells in the
ventricular myocardium is prolonged or abbreviated, as a
result of an alteration in one or more ion channel currents.
T-waves are in large part inscribed as a consequence of the
voltage gradients that develop as a result of transmural
differences in the time course of repolarization. When the
T-wave is upright, the epicardial action potential is the
earliest to repolarize and the M cell (mid-myocardium, papil-
lary muscles, interventricular septum) action potential is the
last. Full repolarization of the epicardium coincides with the
peak of the T-wave. The Tpeak–Tend interval provides an
index of transmural dispersion of repolarization.14 The
cardiac toxicity of LA is attributed to a blockade of sodium
channels in the heart,15 leading to a prolonged conduction
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Fig 3 ECG with extreme T-elevation caused by bupivacaine. Trace before (A), after 1.25 mg kg21 (B), 2.5 mg kg21 (C), and 5 mg kg21 (D) bupi-
vacaine infused (Pig no. 2–9).
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Fig 4 Percentage of pigs with positive T-wave elevation (≥25%
baseline) at different doses bupivacaine infused. n¼15 in both
groups.
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Fig 5 Changes in heart rate (%) after i.v. infusion of 1.25, 2.5, and
5 mg kg21 bupivacaine. n¼15 in both groups.
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time with widening of QRS complexes, changes in QRS mor-
phology, prolongation of PR interval, AV block, and arrhyth-
mias. Owing to altered function of ion channels (mainly
sodium channels, but also calcium and potassium chan-
nels),16 17 not only depolarization but also repolarization is
affected. The exact mechanism for T-wave elevation
caused by intravascular LA administration is not clear.4 6
Also, there is no clear explanation for the huge variability
in the relative increase of T-wave in this study.
The current study included a slow (Group 1) and a fast
dose rate (Group 2) of bupivacaine administration. One
would expect that with slow injection of bupivacaine, a
drug known to have a high first pass lung uptake,18 19 ECG
alterations are reduced, in contrast to fast injection,
causing an excess in plasma concentration of bupivacaine
and related toxicity.20 Interestingly, with slower infusion
rates, ECG changes appeared at lower doses administered.
We hypothesize that although the LA solution was given into
a central vein, the circulation time needed to distribute the
drug from the injection site into cardiac tissue is responsible
for the delay in ECG alteration in the fast group. This reinforces
the necessity that LA should be administered slowly. Not only
to avoid high plasma peak levels but also not to miss
LA-related ECG alterations for early cessation of LA injection.
On the basis of the fact that epinephrine early after a
single LA test dose and bupivacaine alone only later and
after higher doses leads to ECG alterations, for usual clinical
practice, the test dose should contain epinephrine. Whether
a change from an epinephrine containing LA solution after
the test dose to a plain LA solution should be done is
much discussed. Since regional anaesthesia needles or can-
nulas may migrate into a vessel,21 our view is that the full
LA dose administered should contain epinephrine to detect
systemic injection at any period of injection.
In conclusion, this newborn animal model demonstrates
that higher doses of systemically applied bupivacaine can
cause T-elevation. However, bupivacaine-induced T-elevation
is not a reliable indicator to early detect inadvertent systemic
injection of LA and is rather a sign for impeding cardiac tox-
icity, especially during fast injection of LA.
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